<DOC>
	<DOC>NCT00661505</DOC>
	<brief_summary>This single arm study will assess the efficacy, safety and tolerability of once-monthly administration of intravenous Mircera for the maintenance of hemoglobin levels in hemodialysis patients with chronic renal anemia. Patients will receive 4-weekly intravenous injections of Mircera, at a starting dose of 120, 200 or 360 micrograms. The anticipated time on study treatment is 3-12 months, and the target sample size is 100-500 individuals.</brief_summary>
	<brief_title>A Study of Intravenous Mircera in Hemodialysis Patients With Chronic Renal Anemia</brief_title>
	<detailed_description />
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Epoetin Alfa</mesh_term>
	<criteria>adult patients, &gt;= 18 years of age; chronic renal anemia; continuous stable iv or sc maintenance epoetin therapy during previous 4 weeks; regular longterm hemodialysis therapy with the same mode of dialysis for previous 3 months. transfusion of red blood cells during previous 2 months; poorly controlled hypertension requiring hospitalization or interruption of epoetin treatment in previous 6 months; significant acute or chronic bleeding.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
</DOC>